The Business - Cell Therapy Development and Manufacturing (Details) $ in Millions		12 Months Ended
	Mar. 16, 2017 USD ($)	Dec. 31, 2016 client product filing	Mar. 11, 2016
Subsidiary or Equity Method Investee [Line Items]
Equity Method Investment, Ownership Percentage			19.90%
Subsidiary, Ownership Interest by Parent			80.10%
PCT Allendale, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Number of clients worked with (client) \| client		100
Number of products produced (product) \| product		20,000
Number of years since foundation		18 years
PCT Allendale, LLC [Member] \| United States And European Union [Member]
Subsidiary or Equity Method Investee [Line Items]
Number of supported regulatory filings \| filing		50
Subsequent Event [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	80.10%
Hitachi America [Member]
Subsidiary or Equity Method Investee [Line Items]
Equity Method Investment, Ownership Percentage		19.90%	21.00%
Hitachi America [Member] \| Subsequent Event [Member] \| PCT Allendale, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Proceeds From Licensing Agreements	$ 75.0
Forecast [Member] \| Hitachi America [Member]
Subsidiary or Equity Method Investee [Line Items]
Proceeds From Licensing Agreements, Initial Payment	5.0
Proceeds From Licensing Agreements, Closing Payments	5.0
Proceeds From Licensing Agreements, Milestone Payments	5.0
Forecast [Member] \| Hitachi America [Member] \| PCT Allendale, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Cumulative Revenue Threshold for Receiving Milestone Payment	$ 125.0